Bengt Jonsson

Summary

Affiliation: Stockholm School of Economics
Country: Sweden

Publications

  1. ncbi Economic evaluation of proton radiation therapy in the treatment of breast cancer
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Radiother Oncol 75:179-85. 2005
  2. doi Technology assessment for new oncology drugs
    Bengt Jonsson
    Department of Economics, Stockholm School of Economics, Stockholm, Sweden
    Clin Cancer Res 19:6-11. 2013
  3. pmc Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access
    Bengt Jonsson
    Stockholm School of Economics, Stockholm, Sweden
    Hum Vaccin Immunother 8:1360-3. 2012
  4. ncbi Revealing the cost of Type II diabetes in Europe
    B Jonsson
    Centre for Health Economics, Stockholm School of Economics, Box 6501, 113 83 Stockholm, Sweden
    Diabetologia 45:S5-12. 2002
  5. ncbi [Clinical research pays off. Big net profits are to be gained by improved health according to an American study]
    Bengt Jonsson
    Handelshögskolan, Stockholm
    Lakartidningen 103:2542. 2006
  6. ncbi Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds
    Bengt Jonsson
    Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden
    Pharmacoeconomics 22:5-10. 2004
  7. ncbi A review of European studies on the economic burden of brain diseases
    Bengt Jonsson
    Department of Health Economics, Stockholm School of Economics, Stockholm, Sweden
    Eur J Health Econ 5:S4. 2004
  8. ncbi Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial
    Bengt Jonsson
    Stockholm School of Economics, Stockholm, Sweden
    J Hypertens 23:1425-31. 2005
  9. doi Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    B Jonsson
    Stockholm School of Economics, Box 6501, SE 11383 Stockholm, Sweden
    Osteoporos Int 22:967-82. 2011
  10. ncbi An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma
    Bengt Jonsson
    Centre for Health Economics, Stockholm School of Economics, Box 6501 Stockholm 11383, Sweden
    Respir Med 98:1146-54. 2004

Detail Information

Publications49

  1. ncbi Economic evaluation of proton radiation therapy in the treatment of breast cancer
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Radiother Oncol 75:179-85. 2005
    ..It is therefore important to evaluate whether the medical benefits of proton therapy are large enough to justify the higher treatment costs, compared with conventional radiation therapy...
  2. doi Technology assessment for new oncology drugs
    Bengt Jonsson
    Department of Economics, Stockholm School of Economics, Stockholm, Sweden
    Clin Cancer Res 19:6-11. 2013
    ..But without an obvious alternative that is better, the likely future is that HTA will play an increasing role in informing policy decisions aimed at evidence-based cancer care...
  3. pmc Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access
    Bengt Jonsson
    Stockholm School of Economics, Stockholm, Sweden
    Hum Vaccin Immunother 8:1360-3. 2012
    ....
  4. ncbi Revealing the cost of Type II diabetes in Europe
    B Jonsson
    Centre for Health Economics, Stockholm School of Economics, Box 6501, 113 83 Stockholm, Sweden
    Diabetologia 45:S5-12. 2002
    ..The study evaluated more than 7000 patients with Type II diabetes in eight countries -- Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom...
  5. ncbi [Clinical research pays off. Big net profits are to be gained by improved health according to an American study]
    Bengt Jonsson
    Handelshögskolan, Stockholm
    Lakartidningen 103:2542. 2006
  6. ncbi Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds
    Bengt Jonsson
    Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden
    Pharmacoeconomics 22:5-10. 2004
    ..However, these thresholds are not absolute limits; choices about the allocation of healthcare resources are also influenced by other factors, including considerations of equity and the severity of the disease...
  7. ncbi A review of European studies on the economic burden of brain diseases
    Bengt Jonsson
    Department of Health Economics, Stockholm School of Economics, Stockholm, Sweden
    Eur J Health Econ 5:S4. 2004
  8. ncbi Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial
    Bengt Jonsson
    Stockholm School of Economics, Stockholm, Sweden
    J Hypertens 23:1425-31. 2005
    ..Evaluate the cost effectiveness of losartan compared with atenolol from a Swedish national health system perspective...
  9. doi Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    B Jonsson
    Stockholm School of Economics, Box 6501, SE 11383 Stockholm, Sweden
    Osteoporos Int 22:967-82. 2011
    ..Denosumab is cost-effective, particularly for patients at high risk of fracture and low adherence to oral treatments...
  10. ncbi An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma
    Bengt Jonsson
    Centre for Health Economics, Stockholm School of Economics, Box 6501 Stockholm 11383, Sweden
    Respir Med 98:1146-54. 2004
    ..5 microg compared with budesonide 200 microg alone was SEK 21 per symptom-free days gained. The combination of budesonide and formoterol in mild-to-moderate persistent asthma improved effectiveness at modest additional cost...
  11. doi Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden
    Oskar Ström
    Innovus, Stockholm, Sweden
    Acta Orthop 79:269-80. 2008
    ..This prospective observational data collection study assessed the cost and quality of life related to hip, vertebral, and wrist fracture 13-18 months after the fracture, based on 684 patients surviving 18 months after fracture...
  12. ncbi Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)
    Peter Lindgren
    Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden
    Eur J Cardiovasc Prev Rehabil 12:29-36. 2005
    ....
  13. ncbi Proton therapy of cancer: potential clinical advantages and cost-effectiveness
    Jonas Lundkvist
    Stockholm Health Economics, Stockholm, Sweden
    Acta Oncol 44:850-61. 2005
    ..8 million. Investment in a proton facility may thus be cost-effective. The results must be interpreted with caution, since there is a lack of data, and consequently large uncertainties in the assumptions used...
  14. ncbi Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials
    Jenny Berg
    European Health Economics, Stockholm, Sweden
    Clin Ther 29:1184-202. 2007
    ..Several health economic studies have shown that the use of clopidogrel is cost-effective to prevent ischemic events in non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina...
  15. doi Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer
    Mathias Lidgren
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Acta Oncol 47:1018-28. 2008
    ..The aim of this study was to analyse the cost-effectiveness of HER2 testing and trastuzumab in combination with chemotherapy compared with chemotherapy alone from a societal perspective in a Swedish setting...
  16. ncbi The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial
    Anna Ringborg
    Stockholm Health Economics, Stockholm, Sweden
    Eur J Health Econ 6:354-6, 358-62. 2005
    ..Thus the predicted cost-effectiveness ratio of long-term treatment with clopidogrel in patients undergoing PCI is well below the threshold values currently considered cost-effective...
  17. ncbi The societal burden of osteoporosis in Sweden
    Fredrik Borgstrom
    European Health Economics, Stockholm, Sweden
    Bone 40:1602-9. 2007
    ..This burden is substantial and must be acknowledged as an important health problem. Osteoporosis-related fractures do not only lead to high medical care costs but also to high community care costs...
  18. doi The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1
    Peter Lindgren
    i3 Innovus, Stockholm, Sweden
    Pharmacoeconomics 27:221-30. 2009
    ....
  19. ncbi Predictors for high costs of hospital care in elderly hypertensive patients
    Erland Linjer
    Department of Clinical Pharmacology, Sahlgrenska University Hospital, Stockholm, Sweden
    Blood Press 15:245-50. 2006
    ..To analyse predictors of high cost of care in elderly hypertensive patients, in particular costs related to short-term (<10 days) and long-term (< or = 10 days) institutional care...
  20. ncbi Health related quality of life in different states of breast cancer
    Mathias Lidgren
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Qual Life Res 16:1073-81. 2007
    ..The aim of this study was to describe the health related quality of life (HRQoL) in different breast cancer disease states using preference-based measures...
  21. ncbi Health-related quality of life measured with EQ-5D in patients treated for depression in primary care
    Patrik Sobocki
    Karolinska Institutet, Stockholm, Sweden
    Value Health 10:153-60. 2007
    ..The objective of the present study was to assess the impact of depression on patients' health-related quality of life (HRQL) with the EQ-5D instrument over 6 months while on antidepressant treatment...
  22. ncbi The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden
    Peter Lindgren
    Department of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
    Clin Ther 27:100-10. 2005
    ..In addition, a within-trial cost-effectiveness analysis showed favorable costs per event avoided. However, to estimate the long-term effects, a modeling approach is necessary...
  23. doi Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden
    Ulla Wilking
    Karolinska Institutet, Department of Oncology Pathology, Stockholm, Sweden
    Acta Oncol 49:844-50. 2010
    ..Patients with BC are treated within each of the six different Health Care Regions (HCRs) in Sweden. This aim of this project was to study the introduction and usage of trastuzumab in BC in the six HCRs in Sweden...
  24. ncbi Costs and quality of life associated with osteoporosis-related fractures in Sweden
    Fredrik Borgstrom
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Osteoporos Int 17:637-50. 2006
    ....
  25. ncbi Resource use and costs associated with different states of breast cancer
    Mathias Lidgren
    Karolinska Institutet, Stockholm, Sweden
    Int J Technol Assess Health Care 23:223-31. 2007
    ..This study investigated the direct medical resource use and cost, informal care cost, and indirect cost associated with breast cancer in different states of the disease in normal clinical practice...
  26. ncbi Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life
    Mathias Lidgren
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Scand J Gastroenterol 42:867-77. 2007
    ..The treatment of chronic hepatitis C has advanced considerably during the past 15 years. The aim of this study was to evaluate the impact of different key developments from a health-economic perspective...
  27. ncbi Cost of breast cancer in Sweden in 2002
    Mathias Lidgren
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Eur J Health Econ 8:5-15. 2007
    ..The reason that indirect costs were the dominant cost is because most newly detected breast cancers occur in patients aged below 65, thus causing significant production losses due to sick leave, early retirement, and premature mortality...
  28. ncbi Cost of depression in Europe
    Patrik Sobocki
    Medical Management Centre, Department of Learning Informatics Management and Ethics, Karolinska Institutet, Stockholm, Sweden
    J Ment Health Policy Econ 9:87-98. 2006
    ..Yet, the knowledge of the economic impact of depression has been relatively little researched in Europe...
  29. ncbi Model to assess the cost-effectiveness of new treatments for depression
    Patrik Sobocki
    Department of Learning, Informatics, Management and Ethics, Karolinska Institutet and European Health Economics AB, Stockholm, Sweden
    Int J Technol Assess Health Care 22:469-77. 2006
    ..The objective of this study was to develop a model to assess the cost-effectiveness of a new treatment for patients with depression...
  30. ncbi From 4S to IDEAL: the health economics of the statin trials
    Peter Lindgren
    i3 Innovus, Stockholm, Sweden
    Eur J Cardiovasc Prev Rehabil 16:138-43. 2009
    ..New therapies entering the field must now compare favourably with statin therapy, whereas earlier a comparison versus placebo would have been sufficient to demonstrate cost effectiveness...
  31. ncbi Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective
    Peter Lindgren
    Karolinska Institutet, Stockholm, Sweden
    Int J Technol Assess Health Care 23:177-83. 2007
    ..As such, a program is demanding in terms of resources; it is necessary to assess whether it would be money well spent. This determination was the purpose of this study...
  32. ncbi The costs and benefits of regulations for reimbursement of new drugs
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Health Policy 79:337-44. 2006
    ..One potential cost is a delayed introduction of drugs on the market. The objective of this study was to discuss and analyse the time lag between drug authorisation and reimbursement for new chemical entities (NCEs) in Sweden and Finland...
  33. ncbi Cost of disorders of the brain in Europe
    Patrik Andlin-Sobocki
    Stockholm Health Economics, Stockholm, Sweden
    Eur J Neurol 12:1-27. 2005
  34. doi Cost-effectiveness of statins revisited: lessons learned about the value of innovation
    Peter Lindgren
    Innovus, Stockholm, Sweden and Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Klarabergsviadukten 90 D, Stockholm, Sweden
    Eur J Health Econ 13:445-50. 2012
    ..At this point, we can look back on the historical economic data on simvastatin to see what lesson regarding reimbursement we can learn...
  35. ncbi Patient access to rheumatoid arthritis treatments
    Bengt Jonsson
    Department of Economics, Stockholm School of Economics, Stockholm, Sweden
    Eur J Health Econ 8:S35-8. 2008
    ..Since the cost per patient treated with these biological drugs is high compared to previously available treatments, reimbursement through private and public insurance is an important determinant for access to treatment...
  36. ncbi Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery
    Jonas Lundkvist
    European Health Economics, Vasagatan 38, Stockholm, Sweden
    Eur J Health Econ 8:313-23. 2007
    ....
  37. ncbi Pharmacoeconomics of adverse drug reactions
    Jonas Lundkvist
    Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden
    Fundam Clin Pharmacol 18:275-80. 2004
    ..The problem with ADRs is, from an economic point of view, not a problem of minimization but of optimization, to find the right balance between costs and benefits...
  38. ncbi Cost-effectiveness of new drugs: a systematic review of published evidence for new chemical entity drugs introduced on the Swedish market 1987-2000
    Jonas Lundkvist
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Int J Technol Assess Health Care 21:187-93. 2005
    ..The objective of this study was to analyze the amount of cost-effectiveness evidence for new drugs, by systematically reviewing the published evidence of cost-effectiveness...
  39. doi Cost of disorders of the brain in Europe 2010
    Anders Gustavsson
    OptumInsight, Stockholm, Sweden
    Eur Neuropsychopharmacol 21:718-79. 2011
    ..We therefore present much improved cost estimates. Our revised estimates also now include the new EU member states, and hence a population of 514 million people...
  40. ncbi Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study
    Fredrik Borgstrom
    Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
    Pharmacoeconomics 22:1153-65. 2004
    ..The Multiple Outcomes of Raloxifene Evaluation (MORE) study showed that treatment with raloxifene reduces the risk of vertebral fracture and breast cancer in postmenopausal women with osteoporosis...
  41. doi Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea
    Jonas Lundkvist
    i3innovus, Stockholm, Sweden
    J Travel Med 16:28-34. 2009
    ....
  42. ncbi [Drug committees are not necessary--therapeutic recommendations are issued anyway]
    Bengt Jonsson
    Centrum för hälsoekonomi, Handelshögskolan i Stockholm
    Lakartidningen 102:2085-6: discussion 290-2. 2005
  43. pmc A review of breast cancer care and outcomes in Latin America
    Nahila Justo
    OptumInsight Life Sciences, Stockholm, Sweden
    Oncologist 18:248-56. 2013
    ..Early diagnosis and population-wide access to evidence-based treatment remain unresolved problems, despite progress achieved by some countries...
  44. ncbi Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial
    Niklas Zethraeus
    Centre for Health Economics, Stockholm School of Economics, PO Box 6501, SE 113 83 Stockholm, Sweden
    Int J Technol Assess Health Care 21:433-41. 2005
    ..Within a model framework using an individual state transition model, the cost-effectiveness of 50- to 60-year-old women with menopausal symptoms is assessed based on a societal perspective in Sweden...
  45. doi The positioning of economic principles under the changing conditions of the novel drug developmental process in cancer
    Nils Wilking
    Department of Oncology and Radiation Physics, Skane University Hospital, Lund Malmö, Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Chin Clin Oncol 3:23. 2014
    ..e., effect in pivotal clinical trials, is taken into account, but that there is a great need for follow-up studies so that post regulatory approval is able to properly measure population based effects [clinical effectiveness (CLE)]. ..
  46. ncbi Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies
    Niklas Zethraeus
    Stockholm School of Economics, Centre for Health Economics, Stockholm, Sweden
    Pharmacoeconomics 21:39-48. 2003
    ..Based on these advantages the net-benefit approach should strongly be considered when analysing uncertainty in cost-effectiveness analyses...
  47. ncbi Preterm birth in Sweden: what are the average lengths of hospital stay and the associated inpatient costs?
    Anna Ringborg
    Stockholm Health Economics, Stockholm, Sweden
    Acta Paediatr 95:1550-5. 2006
    ....
  48. ncbi Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma
    Jonas Lundkvist
    Medical Management Center, Karolinska Institutet, Stockholm, Sweden
    Cancer 103:793-801. 2005
    ..The objective of the current study was to assess the cost-effectiveness of proton therapy compared with conventional radiation therapy in the treatment of childhood medulloblastoma...
  49. ncbi Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm--a stochastic model of exercise and dietary advice
    Peter Lindgren
    Department of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Prev Med 36:403-9. 2003
    ..Primary prevention may be a way to lower the risk burden of coronary heart disease, but we must establish that preventive programs are cost-effective...